Diamond S G, Markham C H
Neurology. 1983 Aug;33(8):1098-9. doi: 10.1212/wnl.33.8.1098.
We used four disability scales to evaluate eight patients with Parkinson's disease who were treated with pergolide mesylate for 1 year. Disability was rated on all four scales by the same neurologist at each of 11 visits. Prior ratings were not available to the examiner, who did not know that the scales themselves were an object of study. Disability scores, converted to percentage improvement relative to baseline, varied considerably between scales; for instance, at 5 months, one showed 13% improvement and another 58%. At 9 months, one showed worsening of 6% and another showed improvement of 34%. The four disability scales clearly measure different aspects of parkinsonism, and comparing results of different studies may not be valid if the disability scales are not the same.
我们使用四种残疾评定量表对8例接受甲磺酸培高利特治疗1年的帕金森病患者进行评估。在11次就诊时，同一位神经科医生使用这四种量表对残疾情况进行评定。检查者无法获取先前的评定结果，且不知道这些量表本身就是研究对象。残疾评分相对于基线水平转化为改善百分比后，不同量表之间差异很大；例如，在5个月时，一个量表显示改善了13%，而另一个显示改善了58%。在9个月时，一个量表显示恶化了6%，而另一个显示改善了34%。这四种残疾评定量表显然测量的是帕金森病不同方面的情况，如果残疾评定量表不同，比较不同研究的结果可能是无效的。
